BNTX Apr 2024 155.000 call
| Previous close | 2.4000 |
| Open | 2.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 155.00 |
| Expiry date | 2024-04-19 |
| Day's range | 2.4000 - 2.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
Motley FoolWith New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) collaborated on. While the news will certainly help the pharmaceutical companies' bottom lines, it's important to look deeper to see if any of these three stocks make a solid investment today. At first glance, Pfizer's stock appears to be a screaming deal.
Globe NewswireBioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the development of vaccine candidatesData generated by this partnership will contribute to CEPI’s 100 Days Mission, a global effort to accelerate the development of well-tolerated and effective vaccines against future viral threats with pandemic potentialThe partnership is part of BioNTech’s strategy to
Yahoo FinanceUS approval of fall boosters comes amid uptick in COVID-19 cases
The U.S. Food and Drug Administration (FDA) approved updated COVID-19 booster shots today, setting the stage for a fall vaccine push to combat the still-circulating virus.
